Rocket Pharmaceuticals
Stock Forecast, Prediction & Price Target
Rocket Pharmaceuticals (RCKT) stock Price Target by analysts
$40.67
Potential upside: 1269.24%
Rocket Pharmaceuticals price prediction
What is Rocket Pharmaceuticals stock analysts` prediction?
Rocket Pharmaceuticals stock forecast: Based on 2 Wall Street analysts` predicted price targets for Rocket Pharmaceuticals in the last 3 months, the avarage price target is $40.67, with a high forecast of $NaN. The average price target represents a 1269.24% change from the last price of $2.97.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Rocket Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Rocket Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Whitney Ijem Canaccord Genuity | 0% 0/2 | 10 months ago | $39 1213.13% upside | $17.09 | StreetInsider | Previous targets (1) |
Whitney Ijem Canaccord Genuity | 0% 0/2 | 12 months ago | $38 1179.46% upside | $21.8 | StreetInsider | Previous targets (1) |
Michael E Ulz Morgan Stanley | 0% 0/1 | 12 months ago | $45 1415.15% upside | $21.18 | StreetInsider | Previous targets (0) |
Richard Law Goldman Sachs | 0% 0/1 | over 1 year ago | $39 1213.13% upside | $26.72 | StreetInsider | Previous targets (0) |
Unknown Chardan Capital | N/A | almost 3 years ago | $65 2088.55% upside | $15.96 | Benzinga | N/A |
Unknown Raymond James | N/A | almost 3 years ago | $34 1044.78% upside | $15.96 | Benzinga | N/A |
Unknown Evercore ISI | N/A | almost 3 years ago | $75 2425.25% upside | $15.59 | Benzinga | N/A |
Unknown UBS | N/A | almost 3 years ago | $62 1987.54% upside | $13.45 | Benzinga | N/A |
Unknown Raymond James | N/A | about 3 years ago | $24 708.08% upside | $15.17 | Benzinga | N/A |
Unknown Stifel Nicolaus | N/A | about 3 years ago | $56 1785.52% upside | $14.77 | Benzinga | N/A |
Unknown Leerink Partners | N/A | about 3 years ago | $64 2054.88% upside | $15.53 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 3 years ago | $66 2122.22% upside | $9.99 | Benzinga | N/A |
Unknown Needham | N/A | over 3 years ago | $62 1987.54% upside | $9.06 | Benzinga | N/A |
Esther Rajavelu UBS | 0% 0/1 | about 4 years ago | $69 2223.23% upside | $30.8 | StreetInsider | Previous targets (0) |
Rocket Pharmaceuticals Financial Estimates
Rocket Pharmaceuticals Revenue Estimates
Rocket Pharmaceuticals EBITDA Estimates
Rocket Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $117.54M Low: $15.86M High: $200.04M avg. 0% | Avg: $483.52M Low: $61.13M High: $1.02B avg. 311.34% | Avg: $1.00B Low: $126.84M High: $2.13B avg. 107.48% | Avg: $1.65B Low: $208.68M High: $3.50B avg. 64.51% |
Net Income
% change YoY
| $-169.58M N/A | $-219.38M -29.36% | $-245.59M -11.94% | Avg: $-248.14M Low: $-254.00M High: $-161.29M avg. -1.03% | Avg: $-95.16M Low: $-103.98M High: $163.39M avg. 61.64% | Avg: $226.54M Low: $-30.72M High: $558.31M avg. 338.04% | Avg: $508.25M Low: $-68.93M High: $1.25B avg. 124.35% |
EBITDA
% change YoY
| $-163.18M N/A | $-213.68M -30.95% | $-236.62M -10.73% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$2.68 N/A | -$3.22 -20.14% | -$2.92 9.31% | Avg: -$2.44 Low: -$3.02 High: -$1.92 avg. 16.44% | Avg: $0.09 Low: -$1.24 High: $1.94 avg. 103.80% | Avg: $2.7 Low: -$0.37 High: $6.65 avg. 2803.70% | Avg: $6.05 Low: -$0.82 High: $14.91 avg. 124.35% |
Operating Expenses
% change YoY
| $166.24M N/A | $223.84M 34.64% | $259.65M 16.00% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Rocket Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 130.75% in 2025-2028.
We have gathered data from 10 analysts. Their low estimate is -254.00M, average is -248.14M and high is -161.29M.
What is Rocket Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 120.83% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $15.86M, average is $117.54M and high is $200.04M.
What is Rocket Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 762.07% in 2025-2028.
We have gathered data from 10 analysts. Their low earnings per share estimate is -$3.02, average is -$2.44 and high is $-1.92.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Rocket Pharmaceuticals stock. The most successful analyst is Whitney Ijem.